A commitment to innovation and partnership in life science
A passion for success together
At Avalon Biosciences, we are pioneering a new era of biologics innovation to bring transformative therapies to patients worldwide.
Our mission is to accelerate the development and delivery of effective, affordable treatments in oncology, autoimmune diseases, and rare enzyme disorders.
Avalon stands at the intersection of scientific rigor and business acumen—driving innovation, operational excellence, and sustainable value creation for all stakeholders.
.
Our Focus
Backed by cutting-edge platforms and a deep commitment to global health, we integrate robust R&D, clinical, regulatory, and manufacturing capabilities to move novel therapies from gene to market with speed, precision, and scalability.
Our Technology Platform
Avalon Biosciences is built on three synergistic and capital-efficient biologics platforms designed to accelerate the development of novel therapies across high-value indications:
- A powerful Acelazyme™-enabled platform designed to transform the delivery of antibody drugs through efficient and convenient subcutaneous administration.
- A next-generation platform for delivering immunotherapies across the blood-brain barrier, targeting glioblastoma (GBM) and CNS related metastatic cancers
- A versatile enzyme replacement therapy (ERT) platform to address both underserved rare diseases and high-burden global conditions
Our Track Record
Avalon Biosciences is led by a seasoned executive team with a proven track record of building and scaling biotech enterprises across the U.S., China, and global markets.
Our leadership combines deep scientific expertise with strategic execution across R&D, regulatory, capital markets, and global operations.
Collectively, we have advanced over 20 pipeline assets, led blockbuster product development from first-in-class to lifecycle management, and executed IPOs on both NYSE and Nasdaq—raising over $500 million through equity and debt offerings.